-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.

Zhitongcaijing·08/28/2026 13:25:13
Listen to the news
BioNTech's US stock fell about 10% before the market, and the company announced the termination of phase II clinical trials for colorectal cancer.